Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 40th Annual Cowen Health Care Conference on Monday, March 2, 2020 at 3:30 p.m. ET in Boston.

A live audio webcast of the presentation will be available on the Investors & Media section of Stoke’s website at A replay of the webcast will be available for 30 days following the presentations.

About Stoke Therapeutics

Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The company’s lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit or follow the company on Twitter at @StokeTx.

Stoke Therapeutics Inc Stock

Stoke Therapeutics Inc shows a slight decrease today, losing -€0.100 (-0.540%) compared to yesterday.
The community is currently still undecided about Stoke Therapeutics Inc with 1 Buy predictions and 0 Sell predictions.
As a result the target price of €28.00 shows a very positive potential of 51.351% compared to the current price of €18.50 for Stoke Therapeutics Inc.
Like: 0
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.